Vaccine for preventing herpesvirus hominis type II
A herpes simplex virus, vaccine technology, applied in antiviral agents, medical preparations containing active ingredients, gene therapy and other directions, can solve the problems of affecting practical application, low efficiency, etc. The effect of morbidity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0016] Example 1: Obtaining eukaryotic expression plasmid
[0017] Using molecular biology technology PCR method, restriction enzyme digestion, ligation and cloning screening, the original resistance ampicillin (Amp) on the vector pcDNA3 was replaced with Kan resistance (Kan), and then the eukaryotic expression plasmid vector pcDNA3-Kan was constructed. PCR method amplifies the HSV-2 sav strain glycoprotein D full gene sequence (gD), after cloning and recombination, a recombinant plasmid pcDNA-Kan / gD containing gD is obtained. The recombinant plasmid pcDNA-Kan / gD and its specific preparation method have been compared with "He Fang et al. Chinese Journal of Health Inspection, 2008, 18(6): 997-999".
Example Embodiment
[0018] Example 2: Obtaining recombinant plasmid
[0019] Take activated T cells, extract total RNA with Rneasy Mini Kit (QIAGEN), use Oligod(T)n as primer, reverse transcription to synthesize first strand cDNA. With reference to the BC119225.1 sequence included in the NCBI nucleic acid database, a pair of primers was designed, and the synthesized cDNA was used as a template to amplify SEQ ID NO.1. Upstream primer sequence is 5 , -GCC GAATTC ATGATAGAAACATACAGCCAACCT-3 , , The downstream primer sequence is 5 , -GAC CTCGAG TCAGAGTTTGAGTAAGCCAAAAGA-3 , .
[0020] The gene sequence shown in SEQ ID NO. 1 and pcDNA3-Kan were digested with EcoRI and Xho I, and then the gel was purified and recovered. The resulting fragments were recovered and ligated under the action of T4 ligase at a molar concentration of 1:5. The ligation product was transformed into a competent strain of DH5α. The next day, a medium-sized white colony was picked and inoculated in Kan-resistant LB culture medium wi...
Example Embodiment
[0022] Example 3: Using the plasmids obtained in Examples 1 and 2 to immunize mice
[0023] 1. Experimental materials:
[0024] 1) The plasmids obtained in Examples 1 and 2 were amplified in E. coli and purified with QIAGEN purification kit. The concentration and purity of plasmid were determined by ultraviolet spectrophotometry. The concentration and purity of DNA were determined by OD260 and OD280. Plasmid DNA with a ratio of OD260 / OD280 between 1.8 and 2.0 was selected to immunize mice. The two plasmids were stored separately at a low temperature of -20°C, and the mice were thawed before immunization, and the two plasmids were mixed according to the mass ratio of 2:1.
[0025] 2) Freeze storage of HSV-2 virus sav3 repeatedly for three times. After centrifugation, the supernatant was added to the Vero cell monolayer and incubated at 37°C for 1 hour. Remove the virus liquid, add 4% FBS DMEM complete medium, and incubate at 35°C for 24-48h. The adherent cells were scraped off wit...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap